Merck Sharp + Dohme Corp.

Lifearc

British American Tobacco (investments) Limited

Merck Frosst Canada & Co.

British American Tobacco Limited

Stephen John Lewis

Edward Giles Mciver

Jon James Winter-Holt

Joanne Osborne

Timothy Harrison

Andrew Madin

Ian James Collins

Martin Richard Teall

Jose Luis Castro Pineiro

Brian John Williams

Paul Gibson

Andrew Jonathan Bray

Adrian Leonard Smith

Graeme Irvine Stevenson

Timothy Jason Sparey

Kayleigh Webb-Smith

Michael Rowley

Patrice C Belanger

Stephen Robert Fletcher

Alan Douglas Tearle

Joanne Claire Hannam

Martin Ambler

Paul Matthews

Mustafa Isaak Ghulam

Alan John Nadin

Paul Joseph Oakley

Frank Burkamp

Joseph George Neduvelil

Edward Giles McIver

Mark Steven Shearman

Steven Michael Hutchins

Sabrina Bartram

Graham David Checksfield

Isaak Ghulam Mustafa

Packaging for tobacco industry products is disclosed. The packaging comprises a pack for holding tobacco industry products, and an outer wrapper enveloping the pack. The outer wrapper comprises a removable portion arranged to prevent opening of the pack until the removable portion has been removed. One of the pack and the removable portion comprises a tamper evident feature that remains attached to the other of the pack or the removable portion after the removable portion is removed from the pack. A method of packaging tobacco industry products is also disclosed.

Packaging for tobacco industry products

Packaging for tobacco industry products is disclosed. The packaging comprises a pack () for holding tobacco industry products, and an outer wrapper () enveloping the pack. The outer wrapper comprises a removable portion () arranged to prevent opening of the pack until the removable portion has been removed. One of the pack and the removable portion comprises a tamper evident feature that remains attached to the other of the pack or the removable portion after the removable portion is removed from the pack. A method of packaging tobacco industry products is also disclosed.

The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably. Alzheimer's disease. 

Fused thiazolopyrimidine derivatives as MNKs inhibitors

The present invention relates to compounds of formulae I and H, or pharmaceutically acceptable salts or esters thereof. Further aspects of the invention relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease. 

Fused thiazolopyrimidine derivatives as MNKS inhibitors

The present invention relates to compounds of formulae I, or pharmaceutically acceptable salts or esters thereof, wherein: Ris selected from H and CO&#x2014;NRR, wherein Rand Rare each independently selected from H, alkyl, cycloalkyl and mono or bicyclic heterocycloalkyl, wherein said alkyl group is optionally substituted by one or more Rgroups, and said heterocycloalkyl is optionally substituted by Ror R; or Rand Rare linked, together with the nitrogen to which they are attached, to form a heterocycloalkyl group optionally containing one or more additional heteroatoms, and optionally substituted by one or more groups select from Rand (CH)R; Ris selected from H and alkyl, wherein said alkyl group is optionally substituted by one or more Rgroups; Ris selected from alkyl, cycloalkyl and heterocycloalkyl, each of which may be optionally substituted by halo, OH or alkoxy; Z, Z, Zand Zare all C; R, R, Rand Rare each independently selected from H, alkyl, CN, NO, OH, alkoxy, NHCO-alkyl, halo and haloalkyl; or Z, Zand Zare all C, Zis N, Ris absent and R, Rand Rare as defined above; or Z, Zand Zare all C, Zis N, Ris absent and R, Rand Rare as defined above; each Rand R11 is independently alkyl; each Ris independently selected from COR, COOH, OH, alkoxy, haloalkyl, NH, NHR, NRR, heteroaryl and heterocycloalkyl; Ris H or halo. Further aspects relate to pharmaceutical compositions and therapeutic uses of said compounds in the treatment of diseases of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune responses, inappropriate cellular inflammatory responses, or neurodegenerative disorders, preferably tauopathies, even more preferably, Alzheimer's disease. 

Pyrropyrimidine compounds as MNKs inhibitors

Tetrahydroindole derivatives of formula (I): are disclosed. These compounds modulate the activity of gamma-secretase and hence find use in treatment or prevention of Alzheimer's disease. 

Tetrahydroindole derivatives for treatment of alzheimer's disease

A class of compounds is disclosed, comprising sulphonamido-substituted bridged bicycloalkyl structures. The compounds are inhibitors of gamma-secretase, and hence are useful in the treatment of and/or prevention of Alzheimer's disease.

Sulphonamido-substituted bridged bicycloalkyl derivatives

Novel sulfamides of formula (I) are disclosed. The compounds exert an inhibitory action on the processing of APP by gamma-secretase, and are therefore useful in the treatment or prevention of Alzheimer's disease.

Sulfamides as gamma-secretase inhibitors

A class of tryptamine analogues bearing an optionally substituted phenyl nucleus at the 2-position are selective antagonists of the human 5-HT receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse neurological conditions, including psychotic disorders such as schizophrenia.

Phenylindole derivatives as 5-HT2A receptor ligands

Growing community of inventors

East Barnet, United Kingdom

Stephen John Lewis